TrumpRx

Drugs

According to an initial statement from the Trump administration, TrumpRx will provide Eucrisa, Xeljanz, and Zavzpret.^[2] In October 2025, the Trump administration reached a deal with AstraZeneca;^[9] a website from AstraZeneca, named AstraZeneca Direct,^[10] included Farxiga, Airsupra, and FluMist as eligible for direct pricing.^[9] That month, EMD Serono agreed to offer its gonadotropin preparation drugs, including Gonal-f,^[11] on TrumpRx.^[12] AmgenNow, a website from Amgen that offers Repatha, is additionally set to appear on TrumpRx.^[13]

At its launch on February 5, 2026, 43 drugs are available on TrumpRx.^[14] The White House plans to add more drugs over time.^[15] As of February 2026, over half of the medications on TrumpRx currently have or will soon have a more affordable generic version available through various direct-to-consumer platforms, including GoodRx and Mark Cuban's Cost Plus Drugs.^[16] A White House spokesperson mentioned that while cheaper alternatives may exist for certain items on TrumpRx, the site's main advantage lies in offering the lowest-cost options for branded products.^[17]

Political

Bloomberg News described TrumpRx as an instance of Trump using the federal government as an avenue for shareholder activism.^[18]

Senate Democrats, including Ron Wyden, have characterized TrumpRx as resembling a marketing or coupon-based strategy that fails to effectively lower pharmacy costs for the majority of Americans.^[19] They have called for the disclosure of the terms negotiated with manufacturers such as Pfizer and AstraZeneca and have urged regulators to delay the implementation of the initiative until these questions are addressed.^[20] Democratic lawmakers also highlight their own policy proposals such as Medicare negotiation, oversight of pharmaceutical benefit managers (PBMs), and price caps on essential medications as more effective means of reducing drug prices, asserting that TrumpRx does not enhance or replace these measures.^[21][22][23]

Democratic Senators Dick Durbin, Elizabeth Warren, and Peter Welch raised concerns regarding questionable prescribing practices, potential conflicts of interest, and insufficient care related to the specific types of direct-to-consumer (DTC) platforms to which TrumpRx would direct patients.^[24] California Governor Gavin Newsom described TrumpRx as a copy of CalRx, which set the insulin price at a maximum of $11.^[25]

Industry and health

The deal reached with the Trump administration secured Pfizer a reprieve from tariffs on the pharmaceutical industry, threatened to be 100 percent.^[26]

According to The New York Times, TrumpRx does not provide meaningful discounts for insurance beneficiaries.^[27]

Public opinion

A February 2026 YouGov survey found broad support for the new government website when it is not called TrumpRx: 57% approve and 19% disapprove. When the name TrumpRx is used, approval drops to 41% and disapproval rises to 31%. The name has the strongest negative effect among Democrats. Approval falls from 45% to 13% when TrumpRx is mentioned, and disapproval jumps from 27% to 62%. Independents show a similar pattern: approval drops from 49% to 21%, and opinions split evenly (31% approve, 31% disapprove) when the name is used. Republican support remains steady, with strong approval whether or not the name is cited (78% vs. 81%). Mentioning TrumpRx also reduces intended use overall: those “not at all likely” to use the site rise from 35% to 44%. Democrats’ reluctance increases sharply (50% to 74%), as does Independents’ (32% to 45%). Republicans, however, become more likely to use it when the name is mentioned, with “not at all likely” dropping from 23% to 15% and “very likely” rising from 9% to 20%. Overall, the name boosts Republican enthusiasm but lowers broader public support and usage.^[28]